|
Name |
Flavasperone
|
Molecular Formula | C16H14O5 | |
IUPAC Name* |
5-hydroxy-8,10-dimethoxy-2-methylbenzo[h]chromen-4-one
|
|
SMILES |
CC1=CC(=O)C2=C(O1)C3=C(C=C(C=C3C=C2O)OC)OC
|
|
InChI |
InChI=1S/C16H14O5/c1-8-4-11(17)15-12(18)6-9-5-10(19-2)7-13(20-3)14(9)16(15)21-8/h4-7,18H,1-3H3
|
|
InChIKey |
ARXPDHLVDOYIPX-UHFFFAOYSA-N
|
|
Synonyms |
Flavasperone; Asperxanthon; ASPERXANTHONE; Flavasperon; 3566-99-2; Antibiotic TMC 256c2; QUS3F7KQ3E; TMC 256c2; 4H-Naphtho(1,2-b)pyran-4-one, 5-hydroxy-8,10-dimethoxy-2-methyl-; 5-hydroxy-8,10-dimethoxy-2-methyl-4H-naphtho[1,2-b]pyran-4-one; 5-HYDROXY-8,10-DIMETHOXY-2-METHYL-4H-NAPHTHO(1,2-B)PYRAN-4-ONE; UNII-QUS3F7KQ3E; TMD256C2; CHEMBL4645135; SCHEMBL16226658; DTXSID40189166; CHEBI:133814; 5-hydroxy-8,10-dimethoxy-2-methyl-4H-benzo[h]chromen-4-one; 5-Hydroxy-8,10-dimethoxy-2-methyl-4H-naphtho[1,2-b]pyran-4-one, 9CI
|
|
CAS | 3566-99-2 | |
PubChem CID | 5748546 | |
ChEMBL ID | CHEMBL4645135 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 286.28 | ALogp: | 3.3 |
HBD: | 1 | HBA: | 5 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 65.0 | Aromatic Rings: | 3 |
Heavy Atoms: | 21 | QED Weighted: | 0.726 |
Caco-2 Permeability: | -4.798 | MDCK Permeability: | 0.00001770 |
Pgp-inhibitor: | 0.006 | Pgp-substrate: | 0.018 |
Human Intestinal Absorption (HIA): | 0.019 | 20% Bioavailability (F20%): | 0.004 |
30% Bioavailability (F30%): | 0.875 |
Blood-Brain-Barrier Penetration (BBB): | 0.04 | Plasma Protein Binding (PPB): | 80.29% |
Volume Distribution (VD): | 0.924 | Fu: | 14.35% |
CYP1A2-inhibitor: | 0.975 | CYP1A2-substrate: | 0.973 |
CYP2C19-inhibitor: | 0.624 | CYP2C19-substrate: | 0.533 |
CYP2C9-inhibitor: | 0.581 | CYP2C9-substrate: | 0.92 |
CYP2D6-inhibitor: | 0.651 | CYP2D6-substrate: | 0.907 |
CYP3A4-inhibitor: | 0.417 | CYP3A4-substrate: | 0.238 |
Clearance (CL): | 8.048 | Half-life (T1/2): | 0.474 |
hERG Blockers: | 0.005 | Human Hepatotoxicity (H-HT): | 0.231 |
Drug-inuced Liver Injury (DILI): | 0.946 | AMES Toxicity: | 0.583 |
Rat Oral Acute Toxicity: | 0.135 | Maximum Recommended Daily Dose: | 0.781 |
Skin Sensitization: | 0.593 | Carcinogencity: | 0.056 |
Eye Corrosion: | 0.03 | Eye Irritation: | 0.886 |
Respiratory Toxicity: | 0.571 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000962 | 0.758 | D0G4KG | 0.442 | ||||
ENC003504 | 0.662 | D06GCK | 0.411 | ||||
ENC002363 | 0.608 | D0FA2O | 0.346 | ||||
ENC002113 | 0.547 | D04AIT | 0.318 | ||||
ENC006013 | 0.547 | D07MGA | 0.293 | ||||
ENC002134 | 0.532 | D0D4HN | 0.288 | ||||
ENC004845 | 0.526 | D0W7JZ | 0.284 | ||||
ENC003430 | 0.526 | D02LZB | 0.279 | ||||
ENC005716 | 0.523 | D0B0AX | 0.278 | ||||
ENC005717 | 0.523 | D09GYT | 0.273 |